Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial

BACKGROUND: Palonosetron (Aloxi®, Onicit®) is a pharmacologically unique 5-HT(3) receptor antagonist (RA) approved as a single IV injection for the prevention of nausea and vomiting induced by chemotherapy (CINV) of either moderate or highly emetogenic potential (MEC and HEC, respectively). An oral...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Boccia, Ralph, Grunberg, Steven, Franco-Gonzales, Edwin, Rubenstein, Edward, Voisin, Daniel
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer-Verlag 2013
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3612585/
https://ncbi.nlm.nih.gov/pubmed/23354552
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00520-012-1691-5
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky